Borrowing (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 6 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Jun. 25, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Mar. 31, 2025 |
|
| Subordinated Borrowing [Line Items] | |||||||
| Maturity date | Sep. 30, 2030 | ||||||
| Cash and cash equivalents | $ 258,604 | $ 258,604 | $ 164,086 | ||||
| Secured Debt | $ 100,000 | ||||||
| Description Of Future Payment Obligation For Investment Amount | The obligation to make the Payments will cease upon the earliest occurrence of total Payments reaching 1.6 times of the Investment Amount by the calendar quarter ending on June 30, 2031, 1.75 times of the Investment Amount by the calendar quarter ending on June 30, 2034, or 2.0 times of the Investment Amount thereafter. | ||||||
| Debt Instrument, Call Feature | The Company has the right, but not the obligation (the “Call Option”), to buy out the Investor’s interest in the Payments at a repurchase price (the “Put/Call Price”) equal to (a) on or prior to the second anniversary of the Loan Closing Date, an amount equal to 140% of the Investment Amount, less all Payments made to the applicable repurchase date, (b) after the second anniversary but on or prior to August 1, 2031, an amount equal to 160% of the Investment Amount, less all Payments made to the applicable repurchase date, (c) after August 1, 2031 but on or prior to August 1, 2034, an amount equal to 175% of the Investment Amount, less all Payments made to the applicable repurchase date, and (d) after August 1, 2034, an amount equal to 200% of the Investment Amount, less all Payments made to the applicable repurchase date | ||||||
| Aggregate principal amount | 250,000 | $ 250,000 | |||||
| Amortization of debt issuance costs | 671 | $ 18 | |||||
| Loss on debt extinguishment | (9,472) | $ 0 | $ (9,472) | $ 0 | |||
| Convertible Senior Notes due 2032 | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Minimum up payment percent | 130.00% | ||||||
| Aggregate principal amount | $ 1,000,000 | $ 1,000,000 | |||||
| Conversion rate for the Notes | 127.4941 | 127.4941 | |||||
| Common stock conversion price | $ 7.84 | ||||||
| Minimum trading day | 20 days | ||||||
| Consecutive trading day | 30 days | ||||||
| Debt instrument redemption price percentage equal to principal amount | 100.00% | ||||||
| Common stock exceeds percentage | 130.00% | ||||||
| Debt instrument, trading price per share | $ 1,000 | ||||||
| Trading day measurements period | 98.00% | ||||||
| Amortization of debt issuance costs | $ 7,400 | ||||||
| 2026 Capped Call Transactions | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Debt counterparties net cost | $ 17,100 | ||||||
| Cap Price Per Share | $ 10.458 | ||||||
| Food And Drug Administration Approval [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Secured Debt | $ 50,000 | ||||||
| Senior Secured Loan Agreement [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Short-term borrowings outstanding balance | $ 58,700 | ||||||
| Debt Instrument Variable Floor Rate | 4.00% | ||||||
| Variable rate | 6.00% | ||||||
| Percent of Principal amount paid | 3.00% | ||||||
| Secured Debt | $ 50,000 | $ 50,000 | |||||
| Loss on debt extinguishment | 9,500 | ||||||
| Senior Secured Loan Agreement [Member] | Minimum [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Cash and cash equivalents | 25,000 | $ 25,000 | |||||
| Revenue Interest Financing Agreement [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Retained Sales | 1,000,000 | ||||||
| Minimum up payment percent | 100.00% | ||||||
| Revenue Interest Financing Agreement [Member] | Sagard Healthcare Partners [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Related Party Debt | $ 150,000 | ||||||
| Revenue Interest Financing Agreement [Member] | Food And Drug Administration Approval [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Net sales percent | 5.50% | ||||||
| Royalty payment | $ 600,000 | ||||||
| Revenue Interest Financing Agreement [Member] | Maximum [Member] | Food And Drug Administration Approval [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Net sales percent | 3.00% | ||||||
| Royalty payment | $ 1,000,000 | ||||||
| Revenue Interest Financing Agreement [Member] | Minimum [Member] | Food And Drug Administration Approval [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Royalty payment | $ 600,000 | ||||||
| Citigroup Global Markets Inc and Cantor Fitzgerald Company | Convertible Senior Notes due 2032 | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Fixed interest rate on borrowings | 0.75% | ||||||
| Maturity date | Jul. 01, 2032 | ||||||
| Aggregate principal amount | $ 250,000 | $ 250,000 | |||||
| Debt Instrument, Interest Rate, Stated Percentage | 0.75% | 0.75% | |||||
| Additional aggregate principal amount | $ 37,500 | $ 37,500 | |||||
| LongTerm Debt Description | the Company completed its registered underwritten public offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032 (the “Notes”). The Company granted the underwriters an option, exercisable within 30 days of the offering, to purchase up to an additional $37.5 million aggregate principal amount of Notes, issued pursuant to the exercise in full of the overallotment option granted by the Company to the Underwriters (defined below). The Notes were sold pursuant to the Underwriting Agreement, dated June 25, 2026 with Jefferies LLC, Citigroup Global Markets Inc., and Cantor Fitzgerald & Co. as representatives of the several underwriters (the “Underwriters”).The Notes are general unsecured obligations of the Company and bear interest at a rate of 0.75% per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2027. The Notes will mature on July 1, 2032, unless earlier converted, redeemed or repurchased. | ||||||
| Borrowing Two Thousands And Twenty [Member] | Loan Agreements With Bank of Hangzhou [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Short-term borrowings outstanding balance | $ 5,800 | ||||||
| Repayments of short term borrowings | $ 0 | ||||||
| Borrowing Two Thousands And Twenty [Member] | Loan Agreements With Bank of Hangzhou [Member] | Minimum [Member] | |||||||
| Subordinated Borrowing [Line Items] | |||||||
| Fixed interest rate on borrowings | 3.50% | ||||||